Fever of unknown origin

InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, its NLRP3 Inflammasome-targeting Program in Retinal and Kidney Disease

Retrieved on: 
Thursday, September 29, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Diabetes, Clinical Trials, Therapy, Inflammation, Injection, Cytokine, NLRP3, MD, FDA, Food, Biomarker, Recycling, IND, Fever of unknown origin, DME, Retina, Severe cognitive impairment, Diabetic retinopathy, Patient, GA, Cell, Geographic atrophy, Bascom Palmer Eye Institute, Investigational New Drug, Board, AMD, University, Innovation, Food and Drug Administration, Pharmaceutical industry, Vaccine, Ophthalmology

The DRCR Retina Network clinical study in DME will be undertaken at clinical sites in the U.S.

Key Points: 
  • The DRCR Retina Network clinical study in DME will be undertaken at clinical sites in the U.S.
  • Since patients in the trial will be orally dosed, the therapeutic effect of Xiflam on biomarkers of active kidney disease, will be measured as an integral component of the study.
  • And since our drug is orally dosed, a major advantage for patients is that both eyes will be treated concomitantly without the need for injections.
  • InflammX has a follow on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome which will be developed following additional funding being raised.

GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases

Retrieved on: 
Wednesday, September 14, 2022
Autoimmunity, Therapy, Fever of unknown origin, CISC, Safety, Chemically induced dimerization, Knowledge, Inflammatory Bowel Diseases, NK, Patient, TCR, Overactive bladder, Technology, Immune tolerance, Benaroya Research Institute, The Promise, Interleukin, Degenerative disease, T1D, Conference, Bristol Myers Squibb, Multimedia, Seattle Children's, Immune system, Research institute, Vaccine, Pharmaceutical industry, Regulatory T cell, Hai-Genti, Regulatory T cell

CAMBRIDGE, Mass., Sept. 14, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced an upcoming presentation of preclinical data relating to the company's platform technology. The abstract, entitled "Finely Controlled IL-2 Signal in Engineered Human Tregs utilizing a Chemically Induced Signaling Complex (CISC)" will be presented at The Promise of IL-2 Conference in Paris, France on September 16, 2022.

Key Points: 
  • By way of background, Tregsare crucially important in addressing many diseases driven by uncontrolled autologous and allogeneic reactivity.
  • Further, interleukin-2 (IL-2) is the key cytokine for supporting Tregs homeostasis and its functional scarcity underpins many autoimmune diseases.
  • For Tregs therapeutics, IL-2 is essential to support in vivo Tregs stability, proliferation, and persistence, and hence, potency.
  • The company also has a collaboration with Bristol Myers Squibb for the development of Treg therapies for inflammatory bowel diseases.

The Relapsing Polychondritis Foundation Invests in the Next Phase of VEXAS Research

Retrieved on: 
Thursday, March 31, 2022
Disease, Giant cell arteritis, Race, Trachea, Febrile neutrophilic dermatosis, NYU Langone Health, Hematology, Letter, VEXAS syndrome, Classification, Catholic University of Leuven (1834–1968), Internal medicine, Degenerative disease, Genomics, Lists of diseases, Diagnosis, Fever of unknown origin, NEW, Polyarteritis nodosa, Mortality, Cartilage, Inflammation, Nose, Research, Aorta, Episcleritis, RP, Hypoesthesia, Joint, Autoimmune disease, Vacuole, Anemia, UBA1, NIH, Society, Sex linkage, Physician, Science, Genetics, Awareness, Fatigue, Rash, Division, Patient, American Society of Hematology, Pharmaceutical industry, Medical device, Medicine, Animal, VEXAS, Lupus, Rheumatology

NEW YORK, March 31, 2022 /PRNewswire-PRWeb/ --VEXAS is an acronym for: Vacuoles, E1 ubiquitin Activating Enzyme, X-linked, Autoinflammatory, Somatic, with each letter representing one of the hallmark features of this novel autoinflammatory syndrome¹,². The discovery of VEXAS syndrome is revolutionary because it demonstrated that autoimmune disorders previously thought to be unrelated to each other, like relapsing polychondritis (RP), polyarteritis nodosa, Sweet syndrome, and giant cell arteritis, share a common acquired, somatic mutation in the UBA1 gene². UBA1 gene mutations result in the decreased production of an enzyme that breaks-down misfolded proteins and are clinically associated with systemic inflammation, anemia, and bone marrow dysplasia.

Key Points: 
  • To learn more about VEXAS and the research that the RP Foundation's support is expanding upon, check out the following articles:
    1.
  • The Relapsing Polychondritis (RP) Foundation is a 501(c)3, non-profit organization whose mission is to increase awareness and educate the broader community and medical professionals regarding relapsing polychondritis and RP-related autoimmune diseases, and support research initiatives that advance the path to a cure.
  • The Race for RP drives awareness and accelerates research support for the Relapsing Polychondritis Foundation.
  • We're working with the Relapsing Polychondritis Foundation to facilitate research and studies to help diagnose, prevent, and cure RP and its related diseases.

Genomic Testing Cooperative and Their Cooperative Member Laboratories Expand Hematology Panels to Cover VEXAS Disease and a New Prognostic Biomarker in Myeloproliferative Neoplasms

Retrieved on: 
Wednesday, March 2, 2022
Oncology, Health, Genetics, Other Health, Research, Science, Biotechnology, Diagnosis, Pancreatic serous cystadenoma, Acute myeloid leukemia, Aplastic anemia, Lymphatic system, Chondritis, Patient, Multiple myeloma, Prevalence, VEXAS, Cooperative, DOI, Laboratory, DNA, LCA, Gene, Liquid biopsy, Myelodysplastic syndrome, NFE2, Fever of unknown origin, MPN, CA, Sarcoma, Disease, AML, UBA1, Bone marrow, GTC, Vacuole, Vasculitis, Fever, Technology, MD, The, Incidence, Hematology, Chronic myelomonocytic leukemia, Somatic, Sex linkage, Vaccine, Animal, Blood

Genomic Testing Cooperative, LCA (GTC) announced today that their hematology molecular profiling is expanded to cover analysis of the UBA1 and NFE2 genes.

Key Points: 
  • Genomic Testing Cooperative, LCA (GTC) announced today that their hematology molecular profiling is expanded to cover analysis of the UBA1 and NFE2 genes.
  • Detecting the presence of mutations in the UAB1 gene is the only way for confirming the diagnosis of this disease.
  • Testing for these two genes will be included when all hematology profiling tests are ordered from GTC laboratories as well as from the Co-Op member laboratories.
  • These genes are now included in the three hematology tests: Hematology Profile (DNA only), Hematology Profile Plus (DNA+RNA) and Liquid Biopsy Hematology Profile.

GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer

Retrieved on: 
Thursday, February 10, 2022
CFO, MBA, Inflammation, Business, Senior, Autoimmunity, Immune tolerance, Columbia Business School, OverActive Media, Goldman Sachs, Fever of unknown origin, Immune system, Therapy, Applied Genetic Technologies Corporation, Albert Einstein College of Medicine, Patient, Synthetic biology, Biotechnology, JPMorgan Chase, Distinction, Management, Pharmaceutical industry, Allergan, Regulatory T cell, Research

BOSTON, Feb. 10, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced the appointment of Chuck Silberstein, M.D., MBA, as Chief Financial Officer (CFO).

Key Points: 
  • BOSTON, Feb. 10, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced the appointment of Chuck Silberstein, M.D., MBA, as Chief Financial Officer (CFO).
  • A seasoned biotechnology and life sciences executive and licensed physician, Silberstein brings nearly 20 years of experience in investment and capital management, corporate strategy, and business development to the company.
  • In his role as CFO, he will be responsible for directing the company's financial planning, strategy, and stewardship.
  • "I am thrilled to be joining GentiBio at this exciting stage of its development," said Silberstein.

Life-changing Medicines Arcalyst and Gavreto Now Available at AllianceRx Walgreens Prime

Retrieved on: 
Tuesday, September 28, 2021
Transfection, Cancer, Pharmacist, Patient, Recurrence, CAPS, FDA, Pharmacy, DIRA, Heart, Gene, Large-cell lung carcinoma, Solipsism syndrome, Risk, Muckle–Wells syndrome, Maintenance, Pralsetinib, Pericarditis, Cold urticaria, Deficiency, Fever of unknown origin, Pharmaceutical industry

"We are delighted these manufacturers chose AllianceRx Walgreens Prime to dispense these medications.

Key Points: 
  • "We are delighted these manufacturers chose AllianceRx Walgreens Prime to dispense these medications.
  • For full prescribing information and warnings for any of these medicines, visit the manufacturer websites or dailymed.nlm.nih.gov .
  • AllianceRx Walgreens Prime ( alliancerxwp.com ) is a specialty and home delivery pharmacy that strives to provide exceptional care throughout a patient's treatment journey with the medications they need every day.
  • The company is headquartered in Orlando, Fla. and its pharmacies are accredited by several national pharmacy accreditation services.

GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation

Retrieved on: 
Wednesday, August 11, 2021
Autoimmunity, IND, Matrix, Therapy, Company, Patient, Seattle Children's, Research institute, Immune tolerance, Immune system, Fever of unknown origin, RA, Technology, Overactive bladder, Tissue, Inc., Engineering, Multimedia, Degenerative disease, Disease, Regulatory T cell, T1D, Pharmaceutical industry, Vaccine

GentiBio has raised $177 million since 2020 to transcend technical hurdles that have limited the potential of therapeutic Tregs.

Key Points: 
  • GentiBio has raised $177 million since 2020 to transcend technical hurdles that have limited the potential of therapeutic Tregs.
  • The Series A financing will enable GentiBio to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.
  • GentiBio is currently selecting its clinical candidate for T1D and will begin IND-enabling studies before the end of the year.
  • GentiBio's proprietary autologous and allogeneic engineered Tregs platform integrates key complementary technologies needed to successfully (re)establish immune tolerance and overcome major limitations in existing regulatory T cell therapeutics.